Table 1.

Dalbavancin Summary Table

Characteristic	Patient
	1	2	3	4	5	6	7	8
Age at DAL initiation, y/sex	51/M	31/F	40/M	37/F	57/M	64/F	52/M	57/M
Weight, kg	156	128	119	62	76	86	94	103
CrCl at DAL initiation, mL/min	57.1	58.9	18	90	63	32	71	116
Type of LVAD at time of DAL initiation	Heartmate III	Heartmate III	Heartmate III	Heartware	Heartmate III	Heartmate II	Heartmate II	Heartmate III
Reason for LVAD implantation	NICM	PPCM	NICM	PPCM	NICM	ICM	ICM	NICM
LVAD for BTT or DT	DT	DT	BTT	DT	DT	DT	DT	DT
Gram-positive organism(s) identified with previous infection	MRSA	Staphylococcus lugdunensis and Staphylococcus epidermidis	MRSA	MRSA	MRSA and C. Striatium	MSSA	MRSA	S epidermidis and Corynebacterium jeikeium
Other organism(s) identified with previous infection	None	None	Pseudomonas spp	Proteus mirabilis	None	None	None	None
Previous suppression regimen(s)	Doxycycline	Doxycycline and SMX/TMP	Vancomycin	Doxycycline	Doxycycline and minocycline	Cephalexin, doxycycline, SMX/TMP, and linezolid	SMX/TMP and doxycycline	None
Reason for switching suppression to DAL	Breakthrough infection	Breakthrough infection	Breakthrough infection	Breakthrough infection	Breakthrough infection	Adverse effects to oral suppression	Breakthrough infection	NA
Frequency of DAL administration	Biweekly	Biweekly	Biweekly	Biweekly	Biweekly	Weekly, switched to biweekly after 2 mo	Biweekly	Biweekly
Reason for switching DAL to another agent, if applicable	Breakthrough infection	Breakthrough infection	NA	Breakthrough infection	Breakthrough infection	Clinically stable	Breakthrough infection	Clinically stable
Agent DAL was switched to	Linezolid, ceftaroline	Linezolid	NA	Daptomycin and ceftaroline	Vancomycin and daptomycin	Doxycycline	Daptomycin	Minocycline
Gram-positive organism(s) identified with breakthrough infection, if applicable	MRSA	MRSA	NA	MRSA	C. Striatium	NA	MRSA	NA
Time to first LVAD-related infection after DAL suppression initiation, d	112	273	NA	226	251	NA	29	NA
Total duration of DAL for suppression, d	127	273	212	226	372	227	293	107
Missed or delayed infusions	No	No	No	Yes	Yes	No	No	No
Outcome	Continued	Continued	Heart transplantation	LVAD exchange and oral suppression	Continued	Oral suppression	LVAD exchange and oral suppression	Oral suppression

Abbreviations: BTT, bridge to transplant; CrCl, creatinine clearance; DAL, dalbavancin; DT, destination therapy; F, female; ICM, ischemic cardiomyopathy; LVAD, left ventricular assist device; M, male; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible S aureus; NA, not applicable; NICM, nonischemic cardiomyopathy; PPCM, peripartum cardiomyopathy; SMX/TMP, sulfamethoxazole-trimethoprim.